organ
transplant
includ
heart
lung
kidney
liver
pancrea
small
bowel
consid
therapi
choic
endstag
organ
failur
year
organ
implant
worldwid
one
donor
may
provid
multipl
organ
well
cornea
tissu
multipl
recipi
degre
risk
transmiss
infect
carri
graft
notabl
virus
larg
unknown
specif
organ
difficult
assess
approach
microbiolog
screen
organ
donor
vari
nation
region
regul
avail
perform
microbiolog
assay
use
potenti
donor
transmiss
expect
common
unexpect
infect
observ
organ
transplant
gener
recogn
develop
cluster
infect
among
recipi
organ
common
donor
unusu
catastroph
event
data
exist
defin
incid
manifest
donorderiv
infect
ideal
assay
use
screen
prevent
transmiss
absolut
prevent
transmiss
donorderiv
infect
organ
transplant
possibl
howev
improv
screen
technolog
enhanc
safeti
transplant
futur
organ
transplant
therapi
choic
endstag
organ
failur
year
organ
transplant
worldwid
unexpect
transmiss
infect
donor
recipi
infrequ
data
exist
bear
directli
degre
risk
transmiss
donorderiv
infect
transplant
transplant
organ
might
come
donor
unknown
asymptomat
infect
could
contamin
procur
implant
transmiss
infect
facilit
viabl
cell
vascular
organ
moreov
immunosuppress
drug
use
prevent
immunolog
attack
graft
graft
reject
may
amplifi
risk
infect
carri
donor
organ
exampl
west
nile
viru
wnv
report
caus
invas
neurolog
infect
often
immunocompromis
organ
recipi
normal
individu
immunocompromis
host
diminish
inflammatori
respons
sign
symptom
infect
reduc
incid
infect
often
underestim
report
suspect
document
donorderiv
transmiss
event
requir
usa
voluntari
mani
countri
unexpect
diseas
transmiss
occur
less
solid
organ
recipi
contrast
hepat
c
viru
hcv
human
immunodefici
viru
hiv
transmit
screen
blood
product
less
one
million
unit
transfus
screen
process
blood
product
allow
confirmatori
test
enabl
discard
potenti
contamin
blood
limit
suppli
organ
urgent
need
implant
preserv
organ
function
procur
deceas
donor
preclud
prolong
screen
process
discard
potenti
use
graft
data
avail
directli
assess
risk
diseas
transmiss
organ
transplant
studi
difficult
costli
perform
microbiolog
screen
potenti
organ
donor
improv
avail
new
assay
nucleic
acid
test
nat
advanc
antibodi
test
howev
avail
assay
profici
clinic
laboratori
well
nation
regul
govern
report
advers
event
donor
screen
vari
worldwid
region
includ
part
south
america
africa
asia
lack
requir
report
advers
event
transplant
addit
organ
increasingli
share
across
intern
border
identif
cluster
infect
associ
organ
transplant
result
reassess
screen
process
organ
donor
articl
review
major
risk
factor
organdonorderiv
transmiss
infect
opportun
reduc
incid
event
donorderiv
infect
loos
categor
two
group
expect
unexpect
infect
box
distinct
somewhat
arbitrari
mani
ubiquit
pathogen
cytomegaloviru
cmv
gener
detect
avail
microbiolog
assay
pose
known
modest
risk
organ
recipi
gener
infect
treatabl
unexpect
infect
could
result
spread
known
infect
new
region
recent
outbreak
wnv
usa
chikungunya
viru
itali
diagnost
assay
therapi
lack
time
discoveri
within
nation
border
geograph
variat
exist
endem
infect
histoplasmosi
chaga
diseas
caus
parasit
trypanosoma
cruzi
pathogen
screen
assay
might
avail
clinic
laboratori
might
inaccur
exampl
assay
lymphocyt
choriomening
viru
lcmv
tuberculosi
costli
slow
routin
use
donor
screen
could
restrict
specialti
laboratori
screen
assay
organ
donor
must
complet
within
h
identif
potenti
organ
donor
maintain
graft
viabil
screen
data
blood
cultur
might
becom
avail
organ
implant
thu
approach
assess
manag
donorderiv
infect
function
diseas
epidemiolog
avail
diagnost
technolog
cost
screen
data
commun
degre
risk
infect
physician
patient
consid
accept
obtain
lifesav
transplant
might
otherwis
unavail
patient
may
accept
organ
inform
consent
donor
known
infect
infect
gener
treatabl
includ
bacteria
case
donor
pneumonia
sepsi
virus
exampl
hepat
b
viru
hbv
hcv
hiv
individu
infect
hiv
hbv
hcv
may
offer
organ
donor
carri
viru
discuss
given
avail
improv
antivir
therapi
avail
effect
therapi
syphili
tuberculosi
prevent
transmiss
treponema
pallidum
mycobacterium
tuberculosi
recipi
major
infect
result
use
infect
organ
gener
either
due
delay
avail
key
point
unusu
clinic
syndrom
cluster
infect
recipi
organ
donor
suggest
donorderiv
infect
possibl
sourc
transmiss
incid
transmiss
unexpect
infect
organ
allograft
low
precis
data
lack
screen
donor
common
pathogen
involv
epidemiolog
histori
microbiolog
assay
highli
effect
prevent
transmiss
hiv
hepat
b
c
virus
donor
screen
uncommon
pathogen
must
guid
knowledg
chang
local
epidemiolog
infect
key
element
detect
donorderiv
infect
suspicion
part
clinician
care
organ
recipi
applic
newer
microbiolog
techniqu
increas
speed
donor
screen
enhanc
transplant
safeti
microbiolog
data
transplant
team
owe
time
requir
cultur
matur
delay
incomplet
commun
test
laboratori
clinic
site
failur
test
exampl
improperli
perform
assay
occur
hiv
hcv
infect
figur
histor
transmiss
bacteri
infect
prevent
use
surgic
prophylaxi
antibacteri
therapi
given
around
time
transplant
surgeri
emerg
multidrug
antimicrobi
resist
mdr
bacteria
yeast
speci
howev
routin
prophylaxi
might
fail
prevent
transmiss
organ
present
donor
organ
bloodstream
time
procur
increasingli
common
mdr
organ
includ
extendedspectrum
esbl
produc
enterobacteriacea
carbapenemresist
acinetobact
baumannii
crab
klebsiella
pneumonia
crkp
carbapenemresist
enterobacteriacea
cre
transmit
morbid
caus
pathogen
among
organ
recipi
high
among
possibl
risk
factor
donor
colon
mdr
organ
prolong
day
stay
intens
care
unit
critic
ill
requir
vasopressor
support
need
cardio
pulmonari
resuscit
unfortun
donor
hospit
day
suffici
acquir
mdr
infect
clinic
experi
suggest
respiratorycolon
crkpposit
crabposit
organ
donor
may
consid
candid
donor
organ
lung
close
followup
recipi
mandatori
similarli
donor
posit
urin
cultur
crkp
crab
transplant
kidney
avoid
unless
infect
erad
risk
exist
unrecogn
bacter
aemia
caus
organ
presenc
mdr
bacteraemia
transplant
organ
avoid
efficaci
appropri
antimicrobi
treatment
donor
organ
procur
basi
vitro
suscept
data
prevent
recipi
infect
known
gener
period
effect
therapi
also
consid
recipi
transplant
result
microbiolog
cultur
obtain
time
organ
donat
might
avail
implant
given
delay
organ
recipi
may
increas
risk
donorderiv
infect
rapid
commun
complet
microbiolog
suscept
data
organ
procur
organ
clinic
centr
essenti
guid
manag
recipi
infect
may
recogn
donorderiv
may
resist
therapi
immunocompromis
host
potenti
contribut
organ
loss
exampl
mycot
aneurysm
graft
blood
vessel
death
thu
possibl
infect
identifi
fulli
treat
donor
procur
decis
regard
use
organ
might
infect
antimicrobialresist
pathogen
must
made
individu
basi
potenti
organ
recipi
increasingli
travel
abroad
reduc
cost
wait
time
transplant
donor
screen
region
limit
countri
payment
organ
donat
legal
donor
may
tend
come
low
socioeconom
strata
endem
infect
tuberculosi
malaria
chaga
diseas
leishmaniasi
might
common
unpaid
deceas
donor
case
seri
turkey
canada
california
mani
renal
recipi
travel
abroad
organ
develop
sever
infect
often
requir
hospit
travel
organ
donor
socal
transplant
tourist
might
becom
colon
highli
resist
strain
superbug
includ
vancomycinresist
staphylococci
mdr
enterobacteriacea
among
newer
isol
carbapenemas
enzym
call
new
delhi
make
bacteria
resist
wide
rang
anti
microbi
agent
first
identifi
india
sinc
detect
worldwid
resist
trait
compromis
efficaci
almost
anti
microbi
includ
carbapenem
therapeut
option
infect
type
resist
bacteria
larg
limit
colistin
tigecyclin
fosfo
mycin
although
carbapenemas
constitut
critic
medic
issu
infect
yet
report
transplant
set
highli
resist
strain
bacteria
thought
emerg
antimicrobi
pressur
hospit
anim
use
meat
consumpt
via
contamin
fruit
veget
farm
seafood
bacteria
observ
patient
travel
china
india
southeast
asia
middl
east
balkan
australia
region
knowledg
specif
infect
exist
region
provid
transplant
servic
might
guid
patient
evalu
transplant
tourist
might
also
provid
vector
transmiss
new
mdr
organ
medic
institut
consequ
horizont
transmiss
mdr
pathogen
patient
could
occur
could
lead
institutionwid
outbreak
infect
stringent
infect
control
measur
control
spread
mdr
organ
implement
whenev
resist
pathogen
recogn
risk
transmiss
hbv
infect
donor
illustr
potenti
organspecif
pathogen
figur
window
period
microbiolog
screen
potenti
organ
donor
develop
antibodi
respons
pathogen
requir
week
month
initi
infecti
exposur
time
infecti
exposur
develop
antibodi
detect
microbiolog
assay
call
window
period
serolog
test
period
might
result
falseneg
result
nat
measur
viral
nucleic
acid
often
use
signal
amplif
techniqu
depend
perform
characterist
assay
amount
viru
present
clinic
specimen
nat
tend
detect
infect
earlier
greater
sensit
correspond
serolog
test
howev
falseposit
assay
gener
common
nat
test
abbrevi
nat
nucleic
acid
test
transmiss
import
vaccin
transplant
popul
transmiss
hbv
common
absenc
prophylaxi
base
avail
data
liver
transplant
recipi
recent
review
rate
de
novo
hbv
dnh
infect
without
prophylaxi
patient
hbv
nonimmun
recipi
patient
previous
vaccin
individu
patient
isol
recipi
antihbcagposit
posit
antibodi
hbv
core
antigen
patient
natur
immun
recipi
experi
produc
seri
prevent
strategi
prevent
dnh
hbv
surfac
antigen
hbsag
neg
recipi
survey
reveal
indefinit
anti
viral
therapi
commonli
employ
lamivudin
prefer
antivir
agent
antivir
variabl
supplement
hbv
hyperimmun
globulin
hbig
although
entecavir
tenofovir
supplant
lamivudin
treatment
chronic
hbv
infect
often
prophylaxi
liver
transplant
recipi
antihbcagposit
donor
new
studi
use
markov
model
demonstr
lamivudin
remain
costeffect
option
prevent
dnh
context
antihbcagposit
donor
heart
kidney
transplant
recipi
limit
avail
data
suggest
risk
hbv
transmiss
use
organ
antihbcagposit
donor
low
without
posttranspl
antivir
prophylaxi
avail
studi
often
limit
absenc
baselin
data
serolog
statu
presenc
antihb
hbsag
immunosuppress
regimen
donor
recipi
may
affect
transmiss
risk
earli
studi
heart
transplant
recipi
without
prophylaxi
reveal
hbv
transmiss
patient
like
vaccin
transplant
use
donor
heart
consid
safe
may
help
augment
avail
donor
pool
interest
hbv
seroposit
donor
recipi
may
associ
increas
risk
cardiac
allograft
vasculopathi
risk
transmiss
hbv
antihbcagposit
hbsagneg
donor
hbvnaiv
kidney
recipi
vari
definit
transmiss
highli
variabl
includ
acquisit
antihbsag
antihbcag
studi
requir
acquisit
hbsag
detect
hbv
dna
case
definit
risk
transmiss
influenc
recipi
hbv
immun
possibl
prophylaxi
review
nine
studi
evalu
abl
hbsagneg
recipi
kidney
antihbcagposit
donor
new
hbv
serolog
marker
observ
patient
rate
hbsag
acquisit
four
patient
evid
symptomat
hepat
studi
explor
influenc
recipi
antihbsag
statu
use
prophylact
therapi
patient
graft
outcom
wors
among
patient
hbsag
acquisit
evid
antihbsag
antihbcag
seroconvers
given
donor
organ
shortag
temptat
stretch
limit
donat
almost
irresist
unresolv
issu
includ
optim
durat
therapi
donor
bacteraemia
tuberculosi
mening
enceph
unknown
aetiolog
optim
prophylaxi
organ
donor
infect
hbv
hcv
human
herpesviru
human
tcell
lymphotrop
viru
htlv
organ
use
infect
donor
microbiolog
followup
recipi
essenti
basi
risk
factor
identifi
donor
retest
recipi
increas
risk
donor
organ
mandat
usa
elsewher
baselin
month
month
posttransplant
hiv
hcv
hbv
recommend
syphili
expert
also
recommend
long
period
monitor
month
storag
sampl
donor
recipi
blood
plasma
cell
futur
test
nation
guidelin
need
use
organ
donor
known
infect
unexpect
transmiss
donorderiv
infect
estim
occur
less
solid
organ
transplant
recipi
cluster
infect
includ
tuberculosi
fungi
herp
simplex
viru
hsv
lcmv
rabi
viru
cruzi
microsporidiosi
hiv
hcv
found
multipl
recipi
receiv
organ
singl
donor
box
infect
often
caus
pathogen
may
amplifi
immunosuppress
host
asymptomat
mask
normal
organ
donor
clinic
syndrom
trauma
stroke
individu
transmiss
event
might
recogn
unless
clinic
manifest
develop
exampl
donorderiv
chronic
hepat
e
viru
infect
transmiss
identifi
immunosuppress
solid
organ
transplant
recipi
evalu
clinic
hepat
europ
usa
absenc
system
autom
detect
report
posttransplant
infect
among
clinic
centr
procur
organ
recognit
event
depend
clinic
suspicion
transplant
team
confirm
donorderivedinfect
transmiss
event
organ
recipi
notabl
face
unusu
pathogen
requir
special
clinic
laboratori
epidemiolog
investig
public
health
author
intern
consensu
definit
donorderiv
infect
develop
test
donor
potenti
pathogen
imposs
assay
organ
exist
requir
would
substanti
delay
transplant
clinic
recognit
unusu
clinic
syndrom
cluster
organ
recipi
singl
donor
usa
australia
result
develop
new
nat
assay
lcmv
relat
virus
applic
nonspecif
highthroughput
sequenc
tool
capac
detect
unusu
nucleic
acid
sequenc
blood
diagnost
new
arenaviru
cluster
fatal
transplantassoci
infect
standard
microbiolog
techniqu
fail
current
reactiv
statu
potenti
donor
contraind
organ
donat
european
countri
recent
legal
hivposit
recipi
usa
three
hivinfect
donor
use
inadvert
falseneg
test
erron
report
result
transmiss
viru
uninfect
recipi
although
diseas
transmiss
involv
deceas
donor
recent
unexpect
transmiss
hiv
hcv
shown
recipi
organ
live
donor
may
also
risk
donorderiv
hiv
transmiss
gener
bad
outcom
howev
three
patient
receiv
organ
hivinfect
donor
italian
cluster
includ
two
kidney
transplant
recipi
still
aliv
undetect
hivrna
good
tcell
count
function
graft
year
transplant
p
grossi
unpublish
work
transmiss
donorderiv
htlv
report
natur
histori
transmiss
donor
recipi
unknown
given
suboptim
screen
platform
lack
longterm
followup
definit
case
transmiss
solidorgan
donorderiv
diseas
emerg
spain
seroneg
recipi
two
kidney
one
liver
develop
myelopathi
within
year
transplant
viru
ident
sequenc
donor
donor
asymptomat
congenit
infect
donorderiv
death
report
basi
data
countri
low
preval
europ
usa
owe
current
shortag
donor
organ
assess
everi
donor
longer
consid
essenti
current
screen
method
differenti
infect
falseposit
screen
assay
common
util
screen
uncertain
absenc
longterm
followup
data
screen
recommend
endem
area
endem
popul
past
sever
year
emerg
pathogen
wnv
identifi
sourc
donorderiv
infect
transmiss
wnv
organ
transplant
describ
four
recipi
organ
singl
donor
rout
transmiss
rare
screen
organ
donor
wnv
routin
remain
controversi
long
turnaround
time
result
unproven
test
perform
limit
test
avail
made
routin
test
impract
furthermor
transmiss
wnv
occur
absenc
detect
viraemia
seroconvers
organ
donor
low
viral
load
blood
short
durat
viraemia
normal
individu
present
major
problem
nucleic
acid
amplif
test
kidney
may
site
prolong
wnv
replic
shed
anim
human
thu
urin
sampl
could
appropri
blood
wnv
test
organ
donor
futur
prospect
studi
need
verifi
util
routin
wnv
test
urin
blood
organ
donor
rabi
caus
acut
enceph
nearli
uniformli
fatal
unvaccin
host
although
viru
present
anim
reservoir
infect
human
rare
usa
europ
two
cluster
rabi
viru
transmiss
organ
transplant
attribut
bat
canin
rabi
viru
variant
nonvaccin
recipi
develop
initi
unrecogn
rabi
symptom
within
week
transplant
die
observ
suggest
high
rabi
infect
rate
abbrevi
incub
period
unvaccin
immunosuppress
recipi
solid
organ
similar
issu
diseas
recognit
occur
recent
cluster
primari
amoeb
meningoenceph
pam
caus
freeliv
amoeba
three
transplantassoci
cluster
enceph
caus
amoeba
balamuthia
mandrillari
demonstr
risk
associ
solid
organ
transplant
donor
pam
person
hispan
ethni
citi
may
disproportion
affect
unrecogn
skin
lesion
may
preced
enceph
month
year
pool
foreign
donor
increas
unusu
infect
malaria
tuberculosi
chaga
diseas
strongyloidiasi
repres
grow
threat
transplant
recipi
usa
endem
fungi
histoplasma
midwest
coccidioid
southwest
region
repres
notabl
risk
routin
prophylaxi
appli
mani
recipi
notabl
lung
transplant
differenti
diagnosi
fever
enceph
within
first
week
transplant
includ
donorderiv
pathogen
candid
organ
donor
screen
potenti
transmiss
infect
use
medic
social
histori
exampl
past
infect
travel
histori
anim
environment
exposur
sexual
contact
intraven
drug
abus
laboratori
assay
box
physic
examin
perform
avail
microbiolog
data
review
blood
urin
cultur
obtain
organ
preserv
fluid
cultur
countri
although
clinic
relev
data
unclear
standard
screen
transmiss
infect
vari
worldwid
limit
avail
cost
special
assay
platform
nat
epidemiolog
trend
differ
infect
gener
deceas
donor
medic
social
histori
obtain
rel
whose
inform
often
incomplet
thu
organ
procur
organ
depend
batteri
microbiolog
test
box
defin
transmiss
risk
mani
common
infect
evalu
perform
mani
assay
relev
popul
organ
donor
recipi
possibl
presenc
infect
hiv
preclud
organ
donat
countri
region
list
donor
exclus
cri
teria
might
chang
abruptli
base
outbreak
sever
acut
respiratori
syndrom
commonli
known
sar
wnv
chikungunya
viru
donor
infect
untreat
mening
sepsi
consid
rel
contraind
organ
donat
organ
may
use
base
clinic
situat
potenti
recipi
willing
accept
unknown
level
increas
risk
infect
data
infect
consid
context
urgenc
need
potenti
recipi
avail
therapi
treat
infect
ransmiss
occur
organ
donor
candid
recipi
screen
use
serolog
antibodybas
assay
nat
common
expect
infecti
agent
box
result
test
use
guid
deploy
prevent
strategi
prophylaxi
reduc
risk
recipi
infect
use
nat
detect
viral
replic
dnaemia
rnaemia
complement
serolog
test
measur
antibodi
deriv
prior
exposur
vaccin
posit
serolog
antibodi
test
consid
marker
lifelong
latent
infect
pathogen
exampl
herp
famili
virus
cmv
epsteinbarr
viru
hsv
varicella
zoster
viru
commonli
known
chickenpox
seroposit
indic
risk
viral
reactiv
set
immunosuppress
similarli
greatest
risk
infect
viru
cmv
sero
neg
recipi
receiv
organ
seroposit
donor
latent
activ
infect
produc
primari
infect
host
without
prior
immun
recipi
either
monitor
viral
reacti
vation
use
nucleic
acid
antigen
detect
assay
receiv
prophylact
antivir
therapi
prevent
emerg
diseas
although
antivir
antibodi
develop
follow
acut
infect
respons
delay
least
week
exposur
call
window
period
defin
time
exposur
infect
serolog
detect
antibodi
see
figur
thu
immuno
compromis
host
serolog
test
often
use
diagnosi
acut
infect
nat
usual
involv
hybrid
primer
probe
detect
specif
sequenc
circul
viral
nucleic
acid
activ
infect
use
variou
techniqu
pcr
amplifi
gener
signal
result
perform
properli
nat
sensit
specif
gener
high
high
sensit
may
produc
falseposit
result
may
confound
interpret
bk
viru
bkv
associ
nephropathi
also
call
polyomavirusassoci
nephropathi
common
sourc
renal
allograft
dysfunct
loss
kidney
transplant
syndrom
result
bkv
replic
allograft
larg
seri
origin
bkv
replic
kidney
transplant
recipi
investig
analys
viral
sequenc
live
match
donorrecipi
pair
quantit
molecular
assay
donorrecipi
pair
sequenc
viral
type
region
ident
donor
recipi
transplant
consist
donor
deriv
viral
infect
although
sourc
infect
might
consid
importantli
bkv
seropreval
gener
popul
high
exclud
seroposit
donor
kidney
donat
centr
adopt
posttransplant
monitor
bk
viraemia
use
nat
assay
prevent
strategi
base
serolog
test
might
merit
studi
local
epidemiolog
dictat
addit
test
requir
serolog
test
endem
fungi
histoplasma
coccidioid
paracoccidioid
spp
parasit
strongyloid
stercorali
cruzi
use
basi
monitor
prophylaxi
organ
recipi
lung
donor
sputum
cultur
might
provid
evid
fungal
colon
exampl
aspergillu
spp
suggest
enhanc
antifung
prophylaxi
need
recipi
qualiti
microbiolog
screen
depend
nation
standard
clinic
laboratori
term
assay
valid
profici
test
record
commun
result
laboratori
infrequ
perform
specif
assay
might
lack
requir
compet
donor
screen
interpret
serolog
test
result
must
consid
context
specif
donor
condit
exampl
intens
fluid
resuscit
crystalloid
colloid
solut
might
lead
haemodilut
therebi
falseneg
test
wherea
resuscit
blood
product
might
lead
falseposit
test
therebi
mislead
clinic
decisionmak
individu
undergon
fluid
resuscit
nat
test
may
prefer
serolog
howev
nat
test
avail
region
given
high
financi
invest
requir
establish
maintain
test
profici
staf
roundtheclock
avail
moreov
incorrect
data
record
miscommun
delay
test
result
result
transmiss
donorderiv
infect
well
unnecessari
organ
dispos
factor
highlight
need
accur
faster
assay
rapid
complet
evalu
commun
data
us
public
health
servic
guidelin
develop
establish
evidencebas
approach
screen
organ
donor
potenti
carri
increas
risk
transmiss
infect
hiv
hcv
hbv
transplant
recipi
new
guidelin
also
evalu
limit
evid
regard
optim
deploy
nat
donor
screen
virus
previou
guidelin
establish
epidemiolog
risk
factor
hiv
basi
medic
social
histori
donor
updat
guidelin
describ
box
potenti
donor
screen
social
risk
factor
inject
drug
abus
sexual
promiscu
incarcer
sexual
contact
men
may
increas
risk
donorderiv
infect
hbv
hcv
hiv
guidelin
recommend
univers
test
deceas
live
organ
vessel
conduit
spare
vessel
segment
donor
hbv
hcv
hiv
routin
test
donor
known
carri
increas
risk
box
also
includ
use
sensit
assay
hiv
hcv
nat
reduc
likelihood
infect
transmiss
compar
serolog
test
could
miss
activ
infect
window
period
figur
guidelin
recommend
robust
inform
consent
discuss
transplant
candid
medic
decis
maker
clinician
recipi
understand
potenti
risk
benefit
associ
accept
reject
individu
organ
includ
ph
public
health
servic
increas
risk
diseas
transmiss
virusposit
organ
donor
microbiolog
followup
recipi
mandatori
storag
serum
cell
donorrecipi
pair
would
use
recipi
develop
infecti
syndrom
improv
assay
new
pathogen
identifi
futur
develop
guidelin
well
clinic
experi
enc
transmiss
hiv
hcv
hbv
transplant
instruct
respect
develop
screen
strategi
lack
prospect
data
risk
diseas
transmiss
hamper
discuss
risk
term
requir
sensit
assay
deploy
screen
term
discuss
prospect
recipi
routin
use
nat
donor
screen
requir
develop
consensu
around
optim
assay
approach
assay
valid
profici
mainten
educ
regard
data
evalu
improv
mechan
rapid
commun
laboratori
data
clinic
centr
organ
procur
organ
develop
effect
antivir
therapi
hcv
hiv
infect
alter
discuss
regard
risk
transmiss
infect
critic
ill
individu
organ
failur
observ
contrast
lack
transmiss
data
lack
routin
valid
rapid
diagnost
tool
effect
therapi
uncommon
infect
wnv
lcmv
window
period
serolog
test
infect
highli
effect
donor
screen
howev
seroconvers
requir
elabor
antibodi
specif
pathogen
could
delay
sever
week
infecti
exposur
window
period
like
result
falseneg
test
result
could
result
inadvert
transmiss
infect
figur
nat
assay
detect
viral
nucleic
acid
directli
follow
signal
amplif
greater
sensit
specif
serolog
test
result
window
period
hiv
detect
use
nat
reduc
day
use
antibodi
screen
daysa
minimum
day
reduct
potenti
recipi
exposur
use
nat
instead
serolog
figur
similar
reduct
window
period
observ
hcv
hbv
detect
tabl
residu
risk
infecti
transmiss
face
falseneg
serolog
nat
test
estim
low
hiv
hcv
tabl
howev
outbreak
wnv
falseneg
result
detect
serolog
nat
assay
suggest
dual
test
benefici
untreat
infect
qualiti
laboratori
test
essenti
compon
safeti
paradigm
transplant
depend
assay
perform
qualiti
specimen
test
laboratori
techniqu
assay
may
lack
requir
sensit
specif
may
improperli
perform
specimen
may
becom
degrad
contamin
handl
data
may
erron
record
commun
box
criteria
organ
donor
increas
risk
infect
peopl
sex
person
known
suspect
hiv
hbv
hcv
infect
past
month
men
sex
men
preced
month
women
sex
man
histori
sex
men
preced
month
peopl
sex
exchang
money
drug
preced
month
peopl
sex
person
sex
exchang
money
drug
preced
month
peopl
sex
person
inject
drug
intraven
intramuscular
subcutan
rout
nonmed
reason
preced
month
child
less
month
age
born
mother
known
infect
increas
risk
hiv
hbv
hcv
infect
child
breastf
within
preced
month
mother
known
infect
increas
risk
hiv
infect
peopl
inject
drug
intraven
intramuscular
subcutan
rout
nonmed
reason
preced
month
peopl
lockup
jail
prison
juvenil
correct
facil
consecut
hour
preced
month
peopl
newli
diagnos
treat
syphili
gonorrhoea
chlamydia
genit
ulcer
preced
month
peopl
haemodialysi
preced
month
identifi
increas
risk
recent
hcv
infect
intern
qualiti
control
laboratori
procedur
essenti
qualiti
perform
characterist
limit
assay
must
track
organ
procur
organ
cost
infrastructur
requir
need
assur
mainten
profici
may
dictat
use
region
valid
central
test
laboratori
organ
donor
screen
assay
data
may
compar
laboratori
use
differ
commerci
test
laboratorydevelop
socal
home
brew
reagent
new
test
develop
face
chang
epidemiolog
may
lack
valid
larg
clinic
popul
falseposit
falseneg
test
could
occur
result
valid
new
assay
difficult
valid
studi
deceas
live
donor
popul
rare
pathogen
rabi
lcmv
almost
imposs
perform
introduct
new
assay
screen
panel
requir
consider
whether
assay
valid
perform
relev
clinic
laboratori
exampl
even
endem
region
introduct
serolog
test
hepat
e
problemat
owe
sensit
issu
difficulti
perform
rnanat
reliabl
assay
may
use
alloc
discard
organ
test
lifethreaten
untreat
diseas
requir
assay
optim
sensit
thu
confirmatori
test
intern
control
must
employ
detect
falseposit
falseneg
test
broad
array
organ
may
transmit
live
cell
transplant
organ
donor
screen
improv
avail
sensit
microbiolog
assay
target
common
pathogen
incid
infecti
diseas
result
donorderiv
infect
low
although
exact
data
lack
infect
probabl
detect
immunocompromis
recipi
develop
diseas
unusu
sever
infect
low
nativ
virul
sentinel
new
unusu
infect
commun
patient
popul
especi
affect
exampl
inadvert
transmiss
hcv
wnv
chaga
diseas
absenc
highli
sensit
test
key
element
detect
donorderiv
infect
remain
suspicion
part
clinician
care
organ
recipi
present
donorderiv
infect
often
obscur
includ
unexplain
cultureneg
enceph
weak
fever
thrombocytopenia
lympho
cytosi
erythema
surgic
incis
graft
dysfunct
organ
procur
organ
publichealth
author
engag
evalu
incid
microbiolog
identif
donorderiv
pathogen
transplant
recipi
import
enabl
appropri
therapi
affect
individu
recogn
outbreak
infecti
diseas
immunocompromis
host
pathogen
affect
broader
popul
test
protocol
must
adapt
known
chang
epidemiolog
diseas
incorpor
new
technolog
microbiolog
screen
screen
technolog
may
incorpor
new
highthroughput
genet
sequenc
new
sequenc
circul
multiplex
assay
target
mani
specif
pathogen
simultan
singl
assay
identif
potenti
pathogen
organ
implant
also
import
implic
need
rapid
communi
cation
microbiolog
data
clinic
suspicion
clinic
laboratori
clinic
centr
procur
organ
publichealth
author
prospect
research
requir
clarifi
incid
diseas
transmiss
optim
panel
microbiolog
assay
donor
screen
improv
coordin
inform
must
facilit
publichealth
author
clinic
centr
patient
tissu
organ
procur
group
standard
investig
report
terminolog
data
share
potenti
transmiss
event
enhanc
safeti
organ
transplant
worldwid
individu
expos
blood
blood
product
person
hiv
hcv
obtain
paper
use
develop
usph
guidelin
origin
articl
publish
index
medlin
pubm
base
search
term
donorderiv
transmiss
organ
transplant
infect
alon
combin
articl
identifi
fulltext
paper
also
search
refer
list
identifi
articl
relev
paper
